Morgan Stanley Highlights Three Biotech Innovation Investment Opportunities

Morgan Stanley has identified three biotech innovations with the potential to deliver returns to investors. These innovations span Alzheimer's treatment, gene editing, and artificial intelligence (AI).
Analysts Sean Raman and Maxwell Score presented this research during the bank's annual Global Healthcare Conference in New York.
The report estimates the Alzheimer's treatment market at $70 billion, distinguishing between therapies that slow cognitive decline and those targeting symptoms like psychosis and anxiety. The bank notes additional growth potential beyond pharmaceutical companies, as delaying nursing home admissions by 12-18 months could provide multiple times the value to the U.S. healthcare system. Companies in diagnostics, healthcare services, retirement, and insurance may benefit or need to adapt.
Early gene editing therapies involved removing cells outside the body for lab editing before reimplanting them. In contrast, in vivo therapy edits DNA directly within the body, expanding treatment possibilities to organs like the brain, heart, eyes, and liver that cannot be easily removed.
Pharmaceutical and biotech performance has been steadily rising since mid-2025. Morgan Stanley projects the in vivo market to reach $10 billion by 2035, compared to a current consensus of $6 billion. Data expected over the next 18 months could significantly impact investor valuations.
Morgan Stanley prefers AI suppliers over new drug developers, estimating AI can reduce drug discovery timelines from about 4.5 years to 1.5 years and cut R&D costs by 25% to 60%. However, evidence that AI improves patient reach rates for drugs is limited. The bank thus focuses on companies supplying data, tools, and computational capabilities.
These firms are already monetizing technology adoption and relying less on binary clinical outcomes. Morgan Stanley selectively monitors clinical inflection points in AI-focused biotech while approaching large-cap productivity gains cautiously.
Clinical data remains a major driver of biotech stock volatility. Moderna's August rally followed positive late-stage cancer vaccine trial results. Timing also matters: Morgan Stanley strategist Mike Wilson warned of potential 30-day corrections within the next two weeks if oil prices surge in mid-September.
The report suggests real investment opportunities lie outside research labs, with the greatest upside potential tied to clinical data.
Korean Source
This article is an English localization of a Korean-language crypto news report. Original headline: 모건스탠리, 바이오테크 3대 혁신 투자 기회